Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Carla E. M. Hollak, Christoph Wanner et al.|Journal of the American Society of Nephrology|2016Cited by 421
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Lut Boks et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cellsAlisdair McNeill, Anthony H.V. Schapira, Joana Magalhães et al.|Brain|2014Cited by 321
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damageMichael W. J. Cleeter, Anthony H.V. Schapira, Kai‐Yin Chau et al.|Neurochemistry International|2012Cited by 204
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1Pramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|JAMA|2015Cited by 156